LIFETIME RISK OF PROSTATE CANcer
in the United States is currently
estimated to be 16%.1 Although
most cases are found at
an early, curable stage, treatment is
costly and urinary, sexual, and bowelrelated
adverse effects are common.2
Even men who choose active surveillance
as an initial management strategy
face anxiety, uncertain prognosis,
and a measurable risk of sepsis with follow-
up biopsies,3 and more than onethird
of those who initially defer therapy
are ultimately treated.4,5 With such a...
